ADJIENE
Live / Registered — Registered (as of 19 Sept 2023)
What this means for you
Registered since 19 Sept 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97111099
- Registration number
- 7166840
- Mark type
- Stylized text
- Filed
- 05 Nov 2021
- Published for opposition
- 04 Jul 2023
- Registered
- 19 Sept 2023
- Attorney of record
- Michael W. Piper
Goods and services
- Class 005 — Pharmaceuticals: vaccines; medicines for human purpose, namely, pharmaceutical preparations for the treatment of genetic and immune system diseases and disorders, cancer, ophthalmic diseases and conditions, infectious diseases; biological preparations, namely, pharmaceutical preparations for the treatment of genetic and immune system diseases and disorders, cancer, ophthalmic diseases and conditions, infectious diseases; biological preparations for the treatment of cancer; pharmaceutical preparations for the treatment of immune system related diseases and disorders; chemical reagents for medical or veterinary purposes; dietetic beverages and foods adapted for medical use; medical diagnostic reagents; blood products, namely, blood for medical purposes
Owner
- SinoCellTech Ltd., Beijing, CN
- SinoCellTech Ltd., Beijing, CN
- SinoCellTech Ltd., Beijing, CN
Prosecution history
- 19 Sept 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 19 Sept 2023 — REGISTERED-PRINCIPAL REGISTER
- 04 Jul 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 04 Jul 2023 — PUBLISHED FOR OPPOSITION
- 14 Jun 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 01 Jun 2023 — LAW OFFICE PUBLICATION REVIEW COMPLETED
- 25 May 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 15 May 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 15 May 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 15 May 2023 — ASSIGNED TO LIE
- 09 Feb 2023 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 18 Aug 2022 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 18 Aug 2022 — NON-FINAL ACTION E-MAILED
- 18 Aug 2022 — NON-FINAL ACTION WRITTEN
- 16 Aug 2022 — ASSIGNED TO EXAMINER